(Press-News.org) Using biological markers--genetic characteristics that are associated with some patients with breast cancer--can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, says new research from the University of Toronto Mississauga.
"It's been increasingly difficult for pharmaceutical companies to bring new drugs to market," says Jayson Parker, a faculty member in the Department of Biology and medical biotechnology analyst at the University of Toronto. "On average, about 80 per cent of drugs fail at some point in the clinical trial process."
There are currently no clear estimates of success rates in clinical trials for breast cancer drugs and the factors that can impact success. The research team examined clinical trial drug development programs from 1998 to 2012 to determine how often breast cancer drugs were brought to market. The study examined advanced and metastatic breast cancer as well as patients that have been exposed to the chemotherapy drugs taxane and anthracycline.
"We found that only 14 per cent of drugs that undergo human testing for advanced and metastatic breast cancer are eventually approved," says Parker. "This is worse than the average for the industry as a whole."
According to Parker, some researchers have hypothesized that in the era of personalized medicine, biological markers, or biomarkers, could be used to improve clinical trial success rates and help bring more drugs to market faster. To test this hypothesis, Parker and his team examined the clinical trial success rates for drugs tested on breast cancer patients who have a particular biomarker (HER2). Biomarkers form part of the pathway involved in cancer cell development and can influence how a patient responds to therapy.
When the team compared clinical trials that targeted patients with the HER2 biomarker to those that did not, they found the success rate of drug development increased from 15 per cent to 23 per cent.
Improving the success rate of clinical trials also has an economic impact. Parker's team found that using the HER2 biomarker in the design of clinical trials resulted in a cost savings of 27 per cent. "This can means millions of dollars in cost reduction for a clinical trial," says Parker.
Although this finding may be limited to the HER2 biomarker in breast cancer, Parker says the results are encouraging. "This is the first study that has made a systematic comparison between patients with and without a biomarker," he says. "It provides us with concrete initial evidence that the use of a biomarker can help improve clinical trial success rates in breast cancer. We are now exploring whether this finding holds true for other biomarkers in other cancers."
INFORMATION:
Parker conducted the study with graduate students in the UTM Master of Biotechnology program (MBiotech), Nadia Lushina and Prabjot Bal, along with an oncologist at Johns Hopkins Medical School, Dr. Gilberto Lopes and oncologists at Sunnybrook Health Sciences Centre, Dr. Rebecca Dent and Dr. Teresa Petrella. The paper was published in the journal of Breast Cancer Research and Treatment.
MEDIA CONTACTS
Jayson Parker
Department of Biology
University of Toronto at Mississauga
jayson.parker@utoronto.ca
Nicolle Wahl
U of T Mississauga Communications
905-569-4656
nicolle.wahl@utoronto.ca
Biological markers increase clinical trial success rate of new breast cancer drugs
2012-10-01
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Genetically engineered immune system fights melanoma
2012-10-01
MAYWOOD, Il. - Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient's immune system to fight the deadly cancer.
A batch of the immune system's killer T cells will be removed from the patient and genetically modified in a Loyola lab. Two genes will be inserted into the T cells so that they will recognize tumor cells as abnormal.
The patient will undergo high-dose chemotherapy to kill most of his or her remaining T cells. This will make room for the genetically modified ...
AGU journal highlights -- 1 October 2012
2012-10-01
The following highlights summarize research papers that have been recently
published in Geophysical Research Letters (GRL), Journal of Geophysical
Research - Solid Earth (JGR-B), Journal of Geophysical Research - Oceans
(JGR-C), and Water Resources Research (WRR).
In this release:
1. The pros and cons of trading water: A case study in Australia
2. Linking typhoon tracks with rainfall patterns and flood timing
3. Novel observations of currents and drag generated by a tsunami
4. More water stored along major rivers during El Nino years
5. Model suggests Earth ...
New insights on control of pituitary hormone outside of brain has implications for breast cancer
2012-10-01
PHILADELPHIA - The hormone prolactin is produced by the pituitary gland in the brain and then travels via the bloodstream to cells throughout the body, where it exerts multiple reproductive and metabolic effects, most notably on the breast where it is the master regulator of lactation. In recent years researchers have found that prolactin is also produced by some tissues outside the brain, however little is known about the functions of extra-pituitary prolactin or how its production is regulated in these tissues.
Now, the laboratory of Lewis A. Chodosh, MD, PhD, chair ...
Fish getting smaller as the oceans warm: UBC research
2012-10-01
Changes in ocean and climate systems could lead to smaller fish, according to a new study led by fisheries scientists at the University of British Columbia.
The study, published today in the journal Nature Climate Change, provides the first-ever global projection of the potential reduction in the maximum size of fish in a warmer and less-oxygenated ocean.
The researchers used computer modeling to study more than 600 species of fish from oceans around the world and found that the maximum body weight they can reach could decline by 14-20 per cent between years 2000 and ...
Researchers discover key mechanism for controlling the body's inflammatory response
2012-10-01
Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism. The findings, published in Nature Immunology today (30 September), could be exploited in vaccine development and new cancer therapies.
A healthy immune system reacts to danger signals – from microorganisms such as bacteria and viruses, or from the body's own rogue cells, such as cancer cells. This tightly controlled reaction starts ...
Researchers discover gene that causes deafness
2012-10-01
CINCINNATI—Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found a new genetic mutation responsible for deafness and hearing loss associated with Usher syndrome type 1.
These findings, published in the Sept. 30 advance online edition of the journal Nature Genetics, could help researchers develop new therapeutic targets for those at risk for this syndrome.
Partners in the study included the National Institute on Deafness and other Communication Disorders (NIDCD), Baylor College of Medicine and the University of ...
New pathogen epidemic identified in sub-Saharan Africa
2012-10-01
A new study out today (Sunday 30 September) reveals that the emergence and spread of a rapidly evolving invasive intestinal disease, that has a significant mortality rate (up to 45%) in infected people in sub-Saharan Africa, seems to have been potentiated by the HIV epidemic in Africa.
The team found that invasive non-Typhoidal Salmonella (iNTS) disease is caused by a new form of the bacteria Salmonella Typhimurium that has spread from two different focal hubs in Southern and Central Africa beginning 52 and 35 years ago, respectively. They also found that one of the ...
Climate change could cripple southwestern forests
2012-10-01
Combine the tree-ring growth record with historical information, climate records, and computer-model projections of future climate trends, and you get a grim picture for the future of trees in the southwestern United States. That's the word from a team of scientists from Los Alamos National Laboratory, the U.S. Geological Survey, the University of Arizona, and other partner organizations.
If the Southwest is warmer and drier in the near future, widespread tree death is likely and would cause substantial changes in the distribution of forests and of species, the researchers ...
Common RNA pathway found in ALS and dementia
2012-10-01
Two proteins previously found to contribute to ALS, also known as Lou Gehrig's disease, have divergent roles. But a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, shows that a common pathway links them.
The discovery reveals a small set of target genes that could be used to measure the health of motor neurons, and provides a useful tool for development of new pharmaceuticals to treat the devastating disorder, which currently has no treatment or cure.
Funded in part by ...
The genetics of white finger disease
2012-10-01
Vibration-induced white finger disease (VWF) is caused by continued use of vibrating hand held machinery (high frequency vibration >50 Hz), and affects tens of thousands of people. New research published in BioMed Central's open access journal Clinical Epigenetics finds that people with a genetic polymorphism (A2191G) in sirtuin1 (SIRT1), a protein involved in the regulation of endothelial NOS (eNOS), are more likely to suffer from vibration-induced white finger disease.
VWF (also known as hand arm vibration syndrome (HAVS)) is a secondary form of Raynaud's disease involving ...